Association of metformin and statin medications with surrogate measures of cardiovascular disease in youth with type 1 diabetes: the SEARCH for diabetes in youth study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Youth with type 1 diabetes mellitus (T1DM) are at risk of cardiovascular disease (CVD). We evaluated if metformin or statin use was associated with surrogate measures of improved CVD. Methods: We included participants from the SEARCH observational study. Participants treated with insulin plus metformin (n=42) or insulin plus statin (n=39) were matched with 84 and 78 participants, respectively, treated with insulin alone. Measures of arterial stiffness obtained were pulse wave velocity (PWV), augmentation index (AI75), and heart rate variability as standard deviation of the normal-to-normal interval (SDNN) and root mean square differences of successive NN intervals (RMSSD). Results: CVD measures were not significantly different among participants on insulin plus metformin versus those on insulin alone: PWV (5.9±1.0 m/sec vs. 5.8±1.5 m/sec, P=0.730), AI75 (1.8 [-6.0 to 8.0] vs. -2.4 [-10.7 to 3.8], P=0.157), SDNN (52.4 [36.8–71.1] m/sec vs. 51.8 [40.1–74.9] m/sec, P=0.592), and RMSSD (43.2 [29.4–67.6] vs. 47.4 [28.0–76.3], P=0.952). CVD measures were not different for statin users versus nonusers: PWV (5.7±0.8 m/sec vs. 5.9 ±1.1 m/sec, P=0.184), AI75 ( -4.0 [-9.5 to 1.7] vs. -6.7 [-11.3 to 5.7], P=0.998), SDNN (54.6 [43.5–77.2] m/sec vs. 63.1 [44.2–86.6] m/sec, P=0.369), and RMSSD (49.5 [31.2–74.8] vs. 59.2 [38.3–86.3], P=0.430). Conclusion: We found no associations of statin or metformin use with surrogate measures of CVD. Future prospective pediatric clinical trials could address this issue.
Abstract
Purpose: Youth with type 1 diabetes mellitus (T1DM) are at risk of cardiovascular disease (CVD). We evaluated if metformin or statin use was associated with surrogate measures of improved CVD. Methods: We included participants from the SEARCH observational study. Participants treated with insulin plus metformin (n=42) or insulin plus statin (n=39) were matched with 84 and 78 participants, respectively, treated with insulin alone. Measures of arterial stiffness obtained were pulse wave velocity (PWV), augmentation index (AI75), and heart rate variability as standard deviation of the normal-to-normal interval (SDNN) and root mean square differences of successive NN intervals (RMSSD). Results: CVD measures were not significantly different among participants on insulin plus metformin versus those on insulin alone: PWV (5.9±1.0 m/sec vs. 5.8±1.5 m/sec, P=0.730), AI75 (1.8 [-6.0 to 8.0] vs. -2.4 [-10.7 to 3.8], P=0.157), SDNN (52.4 [36.8–71.1] m/sec vs. 51.8 [40.1–74.9] m/sec, P=0.592), and RMSSD (43.2 [29.4–67.6] vs. 47.4 [28.0–76.3], P=0.952). CVD measures were not different for statin users versus nonusers: PWV (5.7±0.8 m/sec vs. 5.9 ±1.1 m/sec, P=0.184), AI75 ( -4.0 [-9.5 to 1.7] vs. -6.7 [-11.3 to 5.7], P=0.998), SDNN (54.6 [43.5–77.2] m/sec vs. 63.1 [44.2–86.6] m/sec, P=0.369), and RMSSD (49.5 [31.2–74.8] vs. 59.2 [38.3–86.3], P=0.430). Conclusion: We found no associations of statin or metformin use with surrogate measures of CVD. Future prospective pediatric clinical trials could address this issue.
참고문헌 (39)
- Maahs DM, "Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association", Circulation, 130, pp.1532~1558 (2014)
- Orchard TJ, "Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study", Diabetes Care, 26, pp.1374~1379 (2003)
- Maahs DM, "Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance", Diabetes, 59, pp.1771~1779 (2010)
- Nadeau KJ, "Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function", J Clin Endocrinol Metab, 95, pp.513~521 (2010)
- Shah AS, "Insulin sensitivity and arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study", J Diabetes Complications, 29, pp.512~516 (2015)
- Cree-Green M, "Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes", Pediatr Diabetes, 17, pp.257~265 (2016)
- Dabelea D, "Cardiovascular risk factors are associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study", Diabetes Care, 36, pp.3938~3943 (2013)
- Rabago Rodriguez R, "Carotid intima-media thickness in pediatric type 1 diabetic patients", Diabetes Care, 30, pp.2599~2602 (2007)
- Vlachopoulos C, "Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis", J Am Coll Cardiol, 55, pp.1318~1327 (2010)
- Dabelea D, "Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood", JAMA, 317, pp.825~835 (2017)
- Shah AS, "Arterial stiffness in adolescents and young adults with and without type 1 diabetes: the SEARCH CVD study", Pediatr Diabetes, 16, pp.367~374 (2015)
- Yu MC, "Arterial stiffness is not increased in teens with early uncomplicated type 1diabetes mellitus", Eur J Pediatr, 171, pp.855~858 (2012)
- Bradley TJ, "Early changes in cardiovascular structure and function in adolescents with type 1 diabetes", Cardiovasc Diabetol, 15, pp.31~ (2016)
- Galler A, "Increased arterial stiffness in children and adolescents with type 1 diabetes: no association between arterial stiffness and serum levels of adiponectin", Pediatr Diabetes, 11, pp.38~46 (2010)
- Jaiswal M, "Reduced heart rate variability among youth with type 1 diabetes: the SEARCH CVD study", Diabetes Care, 36, pp.157~162 (2013)
- Tsuji H, "Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study", Circulation, 94, pp.2850~2855 (1996)
- Kubota Y, "Heart rate variability and lifetime risk of cardiovascular disease: the Atherosclerosis Risk in Communities Study", Ann Epidemiol, 27, pp.619~625.e2 (2017)
- Hillebrand S, "Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression", Europace, 15, pp.742~749 (2013)
- Jaiswal M, "Impact of glycemic control on heart rate variability in youth with type 1 diabetes: the SEARCH CVD study", Diabetes Technol Ther, 15, pp.977~983 (2013)
- Jaiswal M, "Reduced heart rate variability is associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study", Diabetes Care, 36, pp.2351~2358 (2013)
- Fox CS, "Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association", Diabetes Care, 38, pp.1777~1803 (2015)
- Libman IM, "Effect of metformin added to insulin on glycemic control among overweight", obese adolescents with type 1 diabetes: a randomized clinical trial, 2015, pp.314, 2241~2250
- Canas JA, "A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes", Pediatr Diabetes, 16, pp.79~89 (2015)
- Cholesterol Treatment Trialists' (CTT) Collaborators, "Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis", Lancet, 371, pp.117~125 (2008)
- Dabelea D, "Development, validation and use of an insulin sensitivity score in youths with diabetes:the SEARCH for Diabetes in Youth study", Diabetologia, 54, pp.78~86 (2011)
- Al Khalifah RA, "The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis", Pediatr Diabetes, 18, pp.664~673 (2017)
- Anderson JJA, "Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial", J Clin Endocrinol Metab, 102, pp.4448~4456 (2017)
- Petrie JR, "Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial", Lancet Diabetes Endocrinol, 5, pp.597~609 (2017)
- Kershnar AK, "Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study", J Pediatr, 149, pp.314~319 (2006)
- Maahs DM, "Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes", J Pediatr, 150, pp.146~150 (2007)
- Reh CM, "A longitudinal assessment of lipids in youth with type 1 diabetes", Pediatr Diabetes, 12(4 Pt 2), pp.365~371 (2011)
- Specht BJ, "Estimated insulin sensitivity and cardiovascular disease risk factors in adolescents with and without type 1 diabetes", J Pediatr, 162, pp.297~301 (2013)
- Shah AS, "Change in adiposity minimally affects the lipid profile in youth with recent onset type 1diabetes", Pediatr Diabetes, 16, pp.280~286 (2015)
- Guy J, "Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study", Diabetes Care, 32, pp.416~420 (2009)
- Bjornstad P, "Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes", Acta Diabetol, 52, pp.611~619 (2015)
- Dalla Pozza R, "Age of onset of type 1 diabetes in children and carotid intima medial thickness", J Clin Endocrinol Metab, 92, pp.2053~2057 (2007)
- Marcovecchio ML, "ACE inhibitors and statins in adolescents with type 1 diabetes", N Engl J Med, 377, pp.1733~1745 (2017)
- Haller MJ, "Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus", J Pediatr Endocrinol Metab, 22, pp.65~68 (2009)
- American Diabetes Association, "Standards of medical care in diabetes--2017", Diabetes Care, 40(Suppl 1), pp.S1~S131 (2017)